2L+ KRAS G12D Metastatic Pancreatic Adenocarcinoma
RVMDRevolution Medicines IncCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 update for Zoldonrasib/Daraxonrasib (RMC-9805 + RMC-6236) (RAS(ON) Inhibitors) in 2L+ KRAS G12D Metastatic Pancreatic Adenocarcinoma. The expected timing is based on the latest available company guidance and may change.
06/24/26:- Present Phase 1/2 zoldonrasib+dara results in 2L+ KRAS G12D mPDAC on July 2, 2026. 07/02/26:- ESMO GI: zoldonrasib+dara ORR 50% in 2L, 47% in 3L+ mPDAC; Ph3 RASolute 309 planned.
Verification
Confirm timing and program details against the company announcement or filing.